Vascular endothelial growth factor (VEGF)-A165-induced prostacyclin synthesis requires the activation of VEGF receptor-1 and -2 heterodimer.
about
Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarkerTherapy management of cardiovascular adverse events in the context of targeted therapy for metastatic renal cell carcinomaClinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertensionA systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use.A compartment model of VEGF distribution in humans in the presence of soluble VEGF receptor-1 acting as a ligand trapDimerization of VEGF receptors and implications for signal transduction: a computational study.Modulation of angiogenesis by a tetrameric tripeptide that antagonizes vascular endothelial growth factor receptor 1.Vascular endothelial growth factor receptor-2 in breast cancer.Placental growth factor is a potent vasodilator of rat and human resistance arteries.Vascular endothelial growth factor receptor 1 contributes to Escherichia coli K1 invasion of human brain microvascular endothelial cells through the phosphatidylinositol 3-kinase/Akt signaling pathway.VEGFR-1 and VEGFR-2: two non-identical twins with a unique physiognomyExpression of VEGF receptors on endothelial cells in mouse skeletal muscle.Development of an experimental model of proliferative retinopathy by intravitreal injection of VEGF165.Engineered conformation-dependent VEGF peptide mimics are effective in inhibiting VEGF signaling pathways.Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors.Vascular endothelial growth factor receptors: molecular mechanisms of activation and therapeutic potentials.Attenuation of VEGFR-2 expression by sFlt-1 and low oxygen in human placentaA VE-cadherin-PAR3-α-catenin complex regulates the Golgi localization and activity of cytosolic phospholipase A(2)α in endothelial cells.Computational investigation of sphingosine kinase 1 (SphK1) and calcium dependent ERK1/2 activation downstream of VEGFR2 in endothelial cells.The VEGF receptor Flt-1 spatially modulates Flk-1 signaling and blood vessel branching.Vascular endothelial growth factor in eye disease.Vascular endothelial growth factor, its soluble receptor, and hepatocyte growth factor: clinical and genetic correlates and association with vascular function.Inhibition of VEGFR2 Activation and Its Downstream Signaling to ERK1/2 and Calcium by Thrombospondin-1 (TSP1): In silico InvestigationToxicity of sorafenib: clinical and molecular aspects.Bevacizumab-induced hypertension: pathogenesis and management.Vascular endothelial growth factor inhibitor-induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors.Complex receptor-ligand dynamics control the response of the VEGF system to protease injury.Phage display-derived human antibodies in clinical development and therapyBevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients: A systematic review and comprehensive meta-analysis.Quantification and cell-to-cell variation of vascular endothelial growth factor receptors.Phosphorylation of focal adhesion kinase (FAK) on Ser732 is induced by rho-dependent kinase and is essential for proline-rich tyrosine kinase-2-mediated phosphorylation of FAK on Tyr407 in response to vascular endothelial growth factor.Analysing calcium dependent and independent regulation of eNOS in endothelium triggered by extracellular signalling events.Identification of VEGF receptor-2 tyrosine phosphorylation sites involved in VEGF-mediated endothelial platelet-activating factor synthesis.Bevacizumab-induced hypertension: Clinical presentation and molecular understanding.Interactions of VEGF isoforms with VEGFR-1, VEGFR-2, and neuropilin in vivo: a computational model of human skeletal muscle.Quantum dot multiplexing for the profiling of cellular receptors.Molecular Pharmacology of VEGF-A Isoforms: Binding and Signalling at VEGFR2.Computer Simulation of TSP1 Inhibition of VEGF-Akt-eNOS: An Angiogenesis Triple Threat.
P2860
Q24595773-10A7F455-1BDA-406A-9376-3B0FF35D5838Q27013665-DA1070BA-048C-46B5-8C67-A16CA6598000Q28728389-BDD9DC16-2889-4E2B-B82B-E7123A3FFF05Q30433214-D9865C58-8DD0-4862-8145-D97563ECE68AQ30439884-6F45AACA-0F89-4D23-81DC-E893D4B84B4DQ30488864-4624393C-7C01-46A0-AE8D-0633B9C5BCB7Q33376945-ABFA2D03-7ADD-43E2-B5A4-79CB1FA70348Q33912620-82A4FFAE-6359-4A7A-BC8D-199FC909F60AQ34052025-FCE45594-57B9-4D0D-B241-1398AE8ABF92Q34290785-8F288EFC-BDEF-49BC-8F3D-9E0DDE5BCB40Q34333828-189B4F2D-9CD2-4DD1-812E-1E62E5289ADFQ34416113-17307F29-A51B-4200-BE92-BCE8FC386041Q34454886-A5139E7D-E7EB-402A-910F-91638F4DFA04Q34787415-F04B7478-405B-4877-9760-CA6A8739A154Q34803030-29881551-C574-4A77-9A0D-D6D134FDC43FQ35049227-2C2C0D5F-FB5B-4CF6-A32D-630A6413FC53Q35049491-A65F891B-2150-4811-980F-B9891B2FFB12Q35917944-3ABC8131-95A8-41F8-BF01-E31A8DB0AC8AQ36273980-06A7533B-9C7D-4C03-B6A9-E3066020B6F9Q36677542-69A0F779-7DD4-4BF5-92EF-67FBB3A7D789Q36929380-8DDDD637-5ECB-48CE-B059-BC269773DB0FQ37291513-14A4C9CC-A0DC-4A51-84B1-04CA9D90FEC6Q37625434-598A075A-646C-4DB0-96F1-C4BFFBC06ACEQ37676226-CE5BE560-460C-43B5-BABA-22E46DB78494Q37882684-34C6781A-5300-437B-AD66-CD29C38BBA5FQ38156262-909B7568-9AD6-4FAE-BC54-443A5A0B7049Q40244240-7DEC793A-FF90-4B46-81C1-29CDBD04B566Q41416393-7819DA2F-C126-4796-93A7-CA9FCF3C0695Q41612851-822C0DC2-D359-4C7E-BE5E-B7F7B9B4E83FQ41791347-28EEC94F-B4A7-4C3A-8E1A-157C858C9D84Q42093246-BC797927-80C2-43DD-BD02-89ABC0156D9EQ42443326-65784AFF-7585-4696-B151-0F5A6E41BFC9Q42852258-B6E6A03F-43FD-43AB-92A8-105DB473BF7DQ50204127-CCC36021-4F25-415D-BFB2-AB519217EA2EQ51131994-A9E0B150-DBE4-40CA-A838-6C4470B1F8E9Q51717661-1AA8A78F-9656-448E-B969-5B8AADE66764Q52717006-BE84FF07-C361-424C-9830-C4622EC8BF9BQ55413755-3791808C-6745-4590-BA69-4438808EAFE4
P2860
Vascular endothelial growth factor (VEGF)-A165-induced prostacyclin synthesis requires the activation of VEGF receptor-1 and -2 heterodimer.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Vascular endothelial growth fa ...... receptor-1 and -2 heterodimer.
@en
type
label
Vascular endothelial growth fa ...... receptor-1 and -2 heterodimer.
@en
prefLabel
Vascular endothelial growth fa ...... receptor-1 and -2 heterodimer.
@en
P2093
P2860
P356
P1476
Vascular endothelial growth fa ...... receptor-1 and -2 heterodimer.
@en
P2093
Caroline Lemieux
Martin G Sirois
Paul-Eduard Neagoe
P2860
P304
P356
10.1074/JBC.M412017200
P407
P577
2005-01-06T00:00:00Z